Tablets & Capsules

TC0720

Issue link: https://www.e-digitaleditions.com/i/1267517

Contents of this Issue

Navigation

Page 41 of 59

32H July 2020 Tablets & Capsules nologies, Valensa, Parry Nutraceuti- cals, Atacama Bionatural, AstaReal, JXTG Nippon Oil & Energy, Otsuka Pharmaceutical, and Innobio. Vitafoods Europe goes digital GENEVA, Switzerland—Vita- foods Europe, a nutraceutical con- ference and exposition, has can- celed its live event and transitioned to a virtual platform that will take place September 7-11. In addition to educational content, the digital event will allow virtual attendees to connect with industry experts and nutraceutical business own- ers through video networking and matchmaking opportunities. Chr. Hansen acquires UAS Labs MILWAUKEE, WI—Chr. Han- sen has acquired UAS Laboratories, Wausau, WI, a manufacturer of clini- cally-documented probiotics, includ- ing six trademarked strains for diges- tive disorders, immune stimulation, infant probiotics, weight manage- ment, and other health indications. As part of the acquisition, Chr. Han- sen will take over two GMP facilities in Wisconsin with fermentation and downstream processing capacity. Choline supplements during pregnancy may mitigate effects of coronavirus on developing fetus AURORA, CO—Taking choline supplements during early pregnancy may prevent harmful effects on the brain of the developing fetus caused by viral respiratory infections, such as COVID-19, according to a study from the University of Col- orado Anschutz Medical Campus. Researchers analyzed the impact on infant behavior if a mother con- tracted a respiratory infection by measuring the baby's IBQ-R Regula- tion dimension, which evaluates an infant's attention and self-regulatory behaviors. Infants of mothers who had viral infections and took extra choline had significantly higher 3-month IBQ-R scores compared to infants of mothers who had viral infections and did not take extra choline. The study was published in the Journal of Psychiatric Research. increasing demand for natural food supplements, a growing awareness of adverse effects of chemical prod- ucts, and increasing consumer interest in antioxidant dietary supplements will drive market growth. Key mar- ket players include Algatechnologies, Algaecan Biotech, Archer Daniels Midland, BASF, BGG, Cardax, Cya- notech, Divis Laboratories, Fenchem Biotek, Fuji Chemical Industries, Igene BioProduction Technology, DSM, Kunming Biogenic, Supreme Biotech- nutra news Astaxanthin market to grow by 8 percent annually through 2030 ALBANY, NY—The global astax- anthin market is forecast to reach $1.3 billion by 2030, representing a compound annual growth rate of 8 percent, according to a report by Transparency Market Research. Astax- anthin is a naturally occurring dietary component used in supplements. An

Articles in this issue

Links on this page

Archives of this issue

view archives of Tablets & Capsules - TC0720